Latest Breaking News On - Harma and biopharma sectors by the us based prestigious science magazine biocon has been in top 20 global biotech employers ranking since 2012 biologics recognized for world class intellectual property ip management value creation asia pacific region included on elite list 2022 financial highlights consolidated q2fy23 rs crore figures above are rounded off to nearest per cent absolute numbers includes licensing income core ebitda is net ofr ampd expense - Page 1 : comparemela.com
Bengaluru (Karnataka) [India], November 15 (ANI/NewsVoir): Biocon Ltd. (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the second quarter ended September 30, 2022. Leadership Comments Biocon Group "We reported a strong consolidated revenue growth of 23 per cent YoY for Q2FY23 at Rs. 2,384 Crore driven by 34 per cent growth in Biosimilars, 26 per cent in Research Services and 18 per cent in the Generics business. Our Gross R&D spends increased by 52 per cent YoY this quarter to Rs. 252 Crore reflecting our advancing pipeline that will drive our future growth. Core EBITDA was up by 34 per cent at Rs. 816 Crore, representing healthy core operating margins of 35 per cent versus 33 per cent in the same quarter last year. "We have delivered a resilient performance in H1FY23, with all segments delivering strong revenue growth. We expect to consolidate on this performance in the second ha